

**IN THE CLAIMS:**

Please amend claims 1, 2, 19, 26, 54, 83-90 and 95-102.

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. **(Currently amended)** A pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises:
  - a therapeutically effective amount of ~~an extracellular matrix-binding~~ a fragment of Ang-1 protein that binds to the extracellular matrix consisting of SEQ ID NO:1, and/or
  - a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes ~~an extracellular matrix-binding~~ a fragment of Ang-1 protein that binds to extracellular matrix consisting of SEQ ID NO:1.
2. **(Currently amended)** The pharmaceutical composition of claim 1 comprising a therapeutically effective amount of ~~an extracellular matrix-binding~~ a fragment of Ang-1 protein that binds to the extracellular matrix consisting of SEQ ID NO:1.
- 3-18. **(Canceled)**
19. **(Currently amended)** A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant of SEQ ID NO: 13 or SEQ ID NO:14 Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding; wherein said mutant ~~Ang-1~~ is selected from the group consisting of:
  - a peptide having at least 60% ~~homologous~~ homology to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14;
  - ~~an Ang-1~~ a mutant missing a linker domain;
  - ~~an Ang-1~~ a mutant missing an N-terminal coiled-coil region; and

~~an Ang-1~~ a mutant having a serine at residue 265 of SEQ ID NO:13 or SEQ ID NO:14 in place of cysteine.

20-25. **(Canceled)**

26. **(Currently amended)** A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment; wherein said mutant Ang-1 is a peptide having at least 60% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

27-52. **(Canceled)**

53. **(Previously presented)** A pharmaceutical composition comprising  
a) a pharmaceutically acceptable carrier and  
b) a therapeutically effective amount of an Ang-1 fragment with antagonist activity.

54. **(Currently amended)** The pharmaceutical composition of claim 53 further comprising an Ang-2 protein.

55-80. **(Canceled)**

81. **(Previously presented)** The pharmaceutical composition of claim 54 wherein the Ang-1 fragment is an is selected from the group consisting of a SEQ ID NO:11 and SEQ ID NO:12.

82. **(Previously presented)** The pharmaceutical composition of claim 53 wherein the Ang-1 fragment is an is selected from the group consisting of a SEQ ID NO:11 and SEQ ID NO:12.

83. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 70% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

84. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 80% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

85. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 90% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

86. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 95% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

87. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 96% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

88. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 97% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

89. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 98% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

90. **(Currently amended)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 99% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

91. **(Previously presented)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant missing a linker domain.

92. **(Previously presented)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant missing an N-terminal coiled-coil region.

93. **(Previously presented)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant having a serine at residue 265 in place of cysteine.

94. **(Previously presented)** The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant having an amino acid sequence selected from the group consisting of a SEQ ID NO:5. , SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.

95. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 70% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

96. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 80% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

97. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 90% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

98. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 95% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

99. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 96% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

100. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 97% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

101. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 98% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

102. **(Currently amended)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 99% homologous to ~~Ang-1~~ SEQ ID NO: 13 or SEQ ID NO:14.

103. **(Previously presented)** The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is an Ang-1 mutant having an amino acid sequence selected from the group consisting of a SEQ ID NO:5. , SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:10.